Figure 1: Myosin (Myo) IIA and myosin IIB localize to apical epithelial junctions. Figure 2: Differential regulation of myosin IIA and myosin IIB localization at apical junctions. Figure 4: Homophilic ...

Boron, though required only in minimal amounts, is vital for plant development. It strengthens cell walls and supports the growth of roots and shoots. Normally, boron, in the form of boric acid, is ...

"HCM is a heart muscle disease associated with a significant symptom burden. This approval of a new drug, Myqorzo, represents ...

Cytokinetics announced the FDA approval of aficamten to improve functional capacity and symptoms in adults with symptomatic ...

In a decades-long effort, researchers have discovered how to tweak the molecular pathways that turn heart muscle motors up or ...

The novel cardiac myosin inhibitor aficamten improved peak oxygen uptake in symptomatic obstructive hypertrophic cardiomyopathy (HCM), the pivotal SEQUOIA-HCM trial showed. At 24 weeks, the mean ...

The FDA has approved aficamten (Myqorzo; Cytokinetics), a cardiac myosin inhibitor, for adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). 1 ...

The drug is the second cardiac myosin inhibitor to get regulatory signoff in the United States, following mavacamten in 2022.